Novo Nordisk A/S $NVO Shares Sold by Capital International Sarl

Capital International Sarl lessened its position in Novo Nordisk A/S (NYSE:NVO) by 80.7% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 8,563 shares of the company’s stock after selling 35,881 shares during the period. Capital International Sarl’s holdings in Novo Nordisk A/S were worth $475,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Revolve Wealth Partners LLC lifted its holdings in Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after acquiring an additional 200 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of Novo Nordisk A/S by 21.0% in the 1st quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock worth $4,312,000 after purchasing an additional 10,758 shares during the last quarter. Sivia Capital Partners LLC raised its holdings in shares of Novo Nordisk A/S by 18.2% in the 2nd quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock worth $712,000 after purchasing an additional 1,587 shares in the last quarter. Savant Capital LLC raised its holdings in shares of Novo Nordisk A/S by 3.0% in the 2nd quarter. Savant Capital LLC now owns 13,932 shares of the company’s stock worth $962,000 after purchasing an additional 403 shares in the last quarter. Finally, Midwest Trust Co acquired a new stake in Novo Nordisk A/S during the second quarter valued at approximately $599,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

NVO has been the subject of a number of research reports. Morgan Stanley upgraded shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price for the company in a report on Tuesday, March 3rd. TD Cowen downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price objective for the company. in a research report on Tuesday. Argus reissued a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. The Goldman Sachs Group restated a “neutral” rating and issued a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a report on Monday, March 2nd. Finally, Jefferies Financial Group raised Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday, February 12th. Four research analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Novo Nordisk A/S has an average rating of “Hold” and a consensus target price of $49.93.

Novo Nordisk A/S Price Performance

NVO opened at $38.82 on Thursday. The firm has a market capitalization of $173.31 billion, a P/E ratio of 11.19 and a beta of 0.73. The stock has a fifty day moving average of $50.69 and a 200-day moving average of $52.02. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. Novo Nordisk A/S has a 12-month low of $35.85 and a 12-month high of $82.57.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The business had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. Equities analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The business also recently declared a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be given a $1.2751 dividend. This represents a dividend yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio is 52.74%.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Deal with Hims & Hers resolves a legal feud and opens the telehealth channel to sell FDA‑approved Ozempic and Wegovy, which could shift patients away from compounded alternatives and support volume recovery. Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal
• Neutral Sentiment: India’s regulator warned against direct or surrogate advertising for weight‑loss drugs, which could constrain marketing strategies in a fast‑growing market but is not an immediate sales sanction. India warns drugmakers against direct or surrogate weight-loss drug and obesity ads
• Negative Sentiment: FDA issued a warning letter over failures in post‑marketing adverse event reporting tied to semaglutide (Ozempic/Wegovy), citing potential unreported serious events including deaths and a suicide — this raises regulatory risk and a near‑term compliance/oversight overhang. FDA issues warning to Novo Nordisk on unreported semaglutide safety events
• Negative Sentiment: Sell‑side and street pressure: TD Cowen downgraded NVO and other analysts flag that the pipeline may not blunt semaglutide loss‑of‑exclusivity (LOE) headwinds — reinforcing negative sentiment after guidance cuts. Novo Nordisk downgraded as pipeline ‘not poised to blunt semaglutide LOE’
• Negative Sentiment: Investor legal pressure: law firm Pomerantz announced an investigation into Novo Nordisk investors, signaling possible litigation risk and additional headline volatility. Pomerantz law firm investigates claims on behalf of investors of Novo Nordisk
• Negative Sentiment: Competitive pressure: Eli Lilly’s aggressive investments and programs (including China expansion and employer/coverage initiatives) keep the GLP‑1 market intensely competitive, which could pressure Novo’s pricing and market share over time. The Real Reason Eli Lilly Is Pouring $3 Billion Into China

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.